1FG Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
FibroGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.36 |
| 52 Week High | US$2.50 |
| 52 Week Low | US$0.21 |
| Beta | 0.73 |
| 11 Month Change | 45.01% |
| 3 Month Change | 31.32% |
| 1 Year Change | -1.11% |
| 33 Year Change | -96.78% |
| 5 Year Change | -99.03% |
| Change since IPO | -98.08% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1FG | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 5.6% | 0.8% | -1.3% |
| 1Y | -1.1% | -17.5% | 7.4% |
Return vs Industry: 1FG exceeded the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 1FG underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 1FG volatility | |
|---|---|
| 1FG Average Weekly Movement | 24.6% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1FG's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1FG's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 486 | Thane Wettig | www.fibrogen.com |
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.
FibroGen, Inc. Fundamentals Summary
| 1FG fundamental statistics | |
|---|---|
| Market cap | €37.47m |
| Earnings (TTM) | -€116.96m |
| Revenue (TTM) | €172.87m |
0.2x
P/S Ratio-0.3x
P/E RatioIs 1FG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1FG income statement (TTM) | |
|---|---|
| Revenue | US$180.02m |
| Cost of Revenue | US$195.17m |
| Gross Profit | -US$15.16m |
| Other Expenses | US$106.64m |
| Earnings | -US$121.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.21 |
| Gross Margin | -8.42% |
| Net Profit Margin | -67.66% |
| Debt/Equity Ratio | -45.1% |
How did 1FG perform over the long term?
See historical performance and comparison